Podcast: The future of cell and gene therapies

Dan Stanton, Managing editor

April 22, 2021

Collaboration, supply chain resilience, acknowledgement they work, and trust will drive the cell and gene therapy sector going forward, EY’s Adlai Goldberg says on the latest episode of the BioProcess Insider Expression Platform.

The cell and gene therapy sector is on the cusp of flourishing in the vast pharma landscape.

Money is flowing in, manufacturing challenges are being overcome, people are actually being treated and cured. Even COVID-19 may be seen as a driving force for the burgeoning sector. But what does the future hold?


EY’s Adlai Goldberg spoke on the BioProcess Insider Expression Platform podcast

Adlai Goldberg – advisory digital, social, & commercial innovation,  health sciences & wellness, at Ernst & Young – describes the steps industry must take to advance the advanced therapy space and how it must move to balance the individualized autologous approach with more sustainable allogeneic products.

Listen below, or download/stream from Apple iTunes, Google Podcasts, Spotify, or wherever you get your podcasts.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like